Navigation Links
Reata and Abbott Initiate Global Phase 3 Study of Bardoxolone Methyl in Patients With Chronic Kidney Disease and Type 2 Diabetes
Date:6/16/2011

IRVING, Texas and ABBOTT PARK, Ill., June 16, 2011 /PRNewswire/ -- Reata Pharmaceuticals, Inc. and Abbott announced today the initiation of a pivotal Phase 3 clinical trial to evaluate the safety and efficacy of bardoxolone methyl in patients with chronic kidney disease (eGFR of 15-29 mL/min/1.73 m2) and type 2 diabetes.

The trial, known as BEACON (Bardoxolone methyl EvAluation in patients with Chronic kidney disease and type 2 diabetes: the Occurrence of renal eveNts), is the first multinational, double-blind, placebo-controlled study designed to assess the impact of bardoxolone methyl on time to important clinical outcomes. Approximately 1,600 patients at 300 sites worldwide – including in Austria, Australia, Belgium, Canada, Czech Republic, France, Germany, Israel, Italy, Mexico, Spain, Sweden, United Kingdom and United States – will be enrolled in the trial and  randomized 1:1 to receive 20 mg of a reformulated version of bardoxolone methyl or placebo once daily.  Results are expected in 2013.

The primary efficacy endpoint will be a time-to-first-event composite consisting of progression to end-stage renal disease (ESRD), defined as the need for chronic dialysis or renal transplant, and cardiovascular death. Secondary endpoints will include change in estimated glomerular filtration rate (eGFR) and a time-to-first-event composite consisting of hospitalization for congestive heart failure (CHF), non-fatal myocardial infarction (MI), non-fatal stroke and cardiovascular death.

More information on the trial is available at www.clinicaltrials.gov (clinical trial identifier: NCT01351675).

"We are pleased to announce that the Phase 3 BEACON trial is underway," said Pablo E. Pergola, M.D., Ph.D., Director of Renal Associates' Research Di
'/>"/>

SOURCE Abbott
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Public Forum to Discuss Addiction as a Treatable Disease and Highlight National Alcohol and Drug Addiction Recovery Month
2. Oxford Finance Corporation Facilitates Entry for Reata Pharmaceuticals into Asian Markets
3. Abbott and Reata Pharmaceuticals Announce Agreement to Develop and Commercialize Bardoxolone Methyl for Chronic Kidney Disease Outside the U.S.
4. Reata Pharmaceuticals to Present Data from Pivotal Phase 2b Trial in Type 2 Diabetics With Chronic Kidney Disease
5. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
6. Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
7. Abbott Initiates Clinical Study to Evaluate Use of RX Herculink(R) Elite(TM) Renal Stent System for the Treatment of Renal Artery Stenosis
8. Abbotts ABT-874 Shows Positive Results for Maintenance of Response in Phase II Psoriasis Study
9. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
10. Abbott Announces Positive One-Year Results from the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
11. Abbotts m2000(TM) Molecular Diagnostic Instrument and RealTime HIV-1 Test Win Chicago Innovation Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... LA JOLLA, Calif. , Oct. 22, ... RGLS ), a biopharmaceutical company leading ... targeting microRNAs, today announced that it has ... from an ongoing clinical study evaluating RG-101, ... for the treatment of hepatitis C virus ...
(Date:10/20/2014)... , 20 de octubre de 2014  PneumRx, ... campo de la pulmonología intervencional, anunció hoy la ... casi 3 meses antes de lo programado. El Estudio ... de dispositivo de investigación (IDE) aprobada por la ... sistema de espiral de reducción de volumen pulmonar ...
(Date:10/20/2014)...  ResMed (NYSE: RMD ) today ... program, a comprehensive suite of software and service ... health care providers. ResMed Data ... information. It integrates valuable sleep and respiratory treatment ... platforms with customers, in-house or third-party electronic health ...
Breaking Medicine Technology:A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8PneumRx concluye inscripción en prueba fundamental RENEW 2PneumRx concluye inscripción en prueba fundamental RENEW 3ResMed Launches ResMed Data Exchange 2
... the puzzle in helping Canadians gain access to treatments for rare diseases ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... = function(data) { var s = ,; var first_result; // Results are keyed by longUrl, so we need to ...
... Oct. 26 Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ... teleconference with management to provide a general business overview, as ... Wednesday, November 3, 2010, at 5:00 p.m. Eastern Time (2:00 ... September 30, 2010 will be released earlier that day. ...
Cached Medicine Technology:Medunik Canada: a piece of the puzzle in helping Canadians gain access to treatments for rare diseases 2Medunik Canada: a piece of the puzzle in helping Canadians gain access to treatments for rare diseases 3Medunik Canada: a piece of the puzzle in helping Canadians gain access to treatments for rare diseases 4Medunik Canada: a piece of the puzzle in helping Canadians gain access to treatments for rare diseases 5Medunik Canada: a piece of the puzzle in helping Canadians gain access to treatments for rare diseases 6Medunik Canada: a piece of the puzzle in helping Canadians gain access to treatments for rare diseases 7Medunik Canada: a piece of the puzzle in helping Canadians gain access to treatments for rare diseases 8Medunik Canada: a piece of the puzzle in helping Canadians gain access to treatments for rare diseases 9Onyx Pharmaceuticals Announces Third Quarter 2010 Financial Results Teleconference and Webcast 2
(Date:10/22/2014)... October 22, 2014 Hay House is pleased ... Addiction and Upgrade Your Life (Paperback; $10.82) written by the ... & Recovery. This book is meant to help readers ... life of recovery. , Recovery 2.0 is not the ... Recovery 2.0 is a guide for what comes next. ...
(Date:10/22/2014)... Best Cheap Hosting USA is among the most ... recently announced that iPower ( http://www.best-cheap-hosting-usa.com/go/iPower/ ) is the ... the world. , “iPower is one of the most ... various kinds of useful products for new and old ... customer service and a number of features which will ...
(Date:10/22/2014)... Although there are only 24 hours in a ... who have trouble finding time within their busy schedules for exercise ... periods of time to get in shape. Here are five ways ... go. , Change Up Your Commute , Consider riding a ... some exercise into your daily routine. If you must use your ...
(Date:10/22/2014)... Akeso Biomedical, Inc. , a privately held ... infections, microbial biofilms, and chronic wounds, announced that Dr. ... , Dr. Sinskey is a Professor ... of Technology, or MIT. He has been a member ... holds positions as Co-Director of the Malaysia-MIT Biotechnology Partnership ...
(Date:10/22/2014)... TUESDAY, Oct. 21, 2014 (HealthDay News) -- Two sisters ... and heart damage. Ilina and Medha Krishen use ... for sounds of trouble in breathing patterns or heartbeats. ... School in Michigan, wanted to find a way to ... air pollutants. Using an electronic stethoscope, Ilina recorded one ...
Breaking Medicine News(10 mins):Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 2Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 3Health News:Best Cheap Hosting USA Has Recently Announced The Best Cheap Web Hosting Companies In 2014 2Health News:HealthGuideMD Presents Ways to Improve Your Exercise and Fitness 2Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2Health News:Teen Sisters Develop Ways to Measure Lung, Heart Damage 2
... - make rounds to assist those ... ... 700,dialysis patients requiring vital services benefited from the emergency,response efforts enacted by ... kidney care services, during the recent wildfires,affecting areas of Southern California. The ...
... Local residents show America how they ,Think About Their Drink, ST. LOUIS, ... prize winner of the Think About ... The Maples family entered the photo contest by submitting a ... As part of a ...
... they ,Think About Their Drink, NEW HAVEN, Conn., Oct. 29 , WHO: ... among the 25 winning families ... Drink Family Challenge from hundreds of entrants nationwide., WHAT: The ... submitting a creative snapshot of their gangs choosing ...
... 29, 2007 -- Another disease can be added ... Researchers have found that smoking increases the risk ... further, and the risk decreases only slowly after ... and Women,s Hospital, the Harvard School of Public ...
... physicians improve ... administrative burden., ANNAPOLIS, Md., Oct. 29 ... today announced the,introduction of CBayPraxis. (Logo: ... electronic patient folder, a simple,intuitive, and web enabled ...
... is marked by the breakdown of articular cartilage, which ... of most limb bones. It can afflict any ... as well as the weight-bearing knees and hips. ... affected joint. This inflammation has been attributed to ...
Cached Medicine News:Health News:DaVita Emergency Response Efforts Ensure Vital Treatment for More than 700 Kidney Failure Patients in Need of Life-Saving Dialysis Treatments in Areas Affected by Southern California Wildfires 2Health News:MilkPEP: St. Louis Family Wins Nationwide got milk? Contest 2Health News:MilkPEP: St. Louis Family Wins Nationwide got milk? Contest 3Health News:MilkPEP: New Haven Area Families Win Nationwide got milk? Contest 2Health News:MilkPEP: New Haven Area Families Win Nationwide got milk? Contest 3Health News:New study shows smoking increases risk of psoriasis 2Health News:CBaySystems Introduces CBayPraxis - A Breakthrough Solution Focused on Physician Practice Efficiency 2Health News:CBaySystems Introduces CBayPraxis - A Breakthrough Solution Focused on Physician Practice Efficiency 3Health News:CBaySystems Introduces CBayPraxis - A Breakthrough Solution Focused on Physician Practice Efficiency 4Health News:New insights into inflammation in osteoarthritis 2Health News:New insights into inflammation in osteoarthritis 3
... kg, Interior Dimensions (WxDxH): 31.1 x 13.6 ... 44.6 x 22.4 x 20.5 cm, Capacity: ... - 300 x 35 mm bottles, 4 ... 1 - 240 x 80 mm bottle, ...
... The Minifold I system consists of four ... vacuum plenum, and metal clamping plate (see diagram). ... configurations for producing spots, dots, or slots (see ... be purchased as an accessory plate in conjunction ...
... Bio-Dot SF (slot format) microfiltration units provide ... nucleic acid in solution onto nitrocellulose or ... accommodated by using interchangeable templates to form ... format Bio-Dot SF apparatus. Each is available ...
... SF (slot format) microfiltration units provide a ... acid in solution onto nitrocellulose or Zeta-Probe ... by using interchangeable templates to form the ... Bio-Dot SF apparatus. Each is available as ...
Medicine Products: